LIBERATE Endobronchial Valve Study

Clinical Research Study for Severe Emphysema

The LIBERATE Study is evaluating the Zephyr® Endobronchial Valve in patients with severe emphysema. The Zephyr valve is an investigational device designed to reduce the volume of the diseased region of the lung by blocking airflow. As a result, healthy regions may expand and function more efficiently, resulting in improved breathing.

Eligibility requirements include but are not limited to:

  • Diagnosed with emphysema
  • Non-smoking for > 4 months before screening examination
  • Agree to participate in a pulmonary rehabilitation program, both before and after enrollment in the study

To learn if you may be a candidate for the study, take the brief screening survey or call 888-248-LUNG (888-248-5864).

As with any clinical study, the LIBERATE Study involves potential risks. Prior to participation, your doctor will review benefits and risks that may be associated with device and study.

Additional information on the LIBERATE Clinical Study is available at www.clinicaltrials.gov.

CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.
US / new visitor